; (I) estimated global and domestic sales of the drug; (J) gross and net expenditures by public payers for coverage of the drug under Federal health programs, to the extent available; and (K) any additional information the Academy determines appropriate; (2) an appropriate timeline for the submission of information to the Drug Affordability and Access Committee required under section 6(a)(2) to determine the reasonableness of a drug’s manufacturer list price and retail price